An artificial intelligence (AI) tool developed by researchers at NewYork-Presbyterian and Columbia University Irving Medical Center, Pathway Labs’ EchoNext, has received the world’s first FDA clearance for AI detection of hidden heart disease through electrocardiograms (ECGs).

A new gene therapy appears to be safe in patients diagnosed with Friedreich ataxia cardiomyopathy, a progressive and fatal inherited cardiac disease, according to a phase 1 clinical trial led by Weill Cornell Medicine researchers.

Extreme heat and cold are growing cardiovascular risks that can trigger heart attacks, strokes, heart failure, and sudden cardiac death, according to a recent scientific statement by experts at Weill Cornell Medicine, Columbia University, and other leading institutions.

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.

NewYork-Presbyterian today announced a Request for Proposals (RFP) for the Community Fund, the hospital’s largest grant opportunity for community-based organizations (CBOs).

Doctors should consider treating high cholesterol much earlier and more aggressively than they have in the past, according to a new perspective by Weill Cornell Medicine, NewYork-Presbyterian and Yale School of Medicine investigators.

All NewYork-Presbyterian hospitals now have a five-star rating from the Centers for Medicare & Medicaid Services (CMS), the highest rating in CMS’s annual quality measurement program for hospitals.

Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain most—but not all—of their weight loss, according to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.